哪里想瘦打哪里！FDA批准Kythera注射药品上市在即

你才双下巴，你全家都双下巴！所谓大方有心人皆有之。如果说赘肉是每一个愿意握有完美身材的“妹纸”或“汉纸”的大敌，那么一个人情味十足的双下巴堪称是这些人的世间仇敌了。每一分钟，多国都有人为自己的一张大饼脸而感到烦恼，虽然握有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的扎实使其难以承受一个双下巴之重。您可千万别笑，这甚至已经催生出一个庞大的市场需求。根据American皮肤外科手术协则会的清查研究推断，68%的American黑人对自己的双下巴表示了“厌倦”之情。而有鉴于此，最近Kythera一些公司向FDA提交了其的机构歼灭双下巴的护肤品施打样式药剂ATX-101。这种药剂完毕了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，堪称是定点节食。免得以为这种即便如此温柔的药剂只是一个笑话，在FDA辖下的皮肤和诊疗药剂法律顾问则会的无记名投票中所，医学专家可是以17：0的超高投票率赞同赞同其纳斯达克。或许是因为这些医学专家中所也有很多遭致双下巴之苦吧。FDA也将计划于本年的5月13日之前对其作出最后决定。如果一切顺利的话，Kythera一些公司计划于本年年初将该产品纳斯达克，分析人士预定这一药剂的零售业将高达3亿美元之多。随着护肤品药剂市场需求的日趋升高，Kythera一些公司堪称是下了一步好棋。一些公司于本年以8400万美元的单价从其前伙伴穆勒手中所归还了这种药剂的全部权利。而Kythera一些公司也愿意以此为借此机则会在护肤品药剂市场需求中所攻城拔寨。就在上个月，Kythera一些公司和Actelion一些公司达成价值2700万美元的合作协定，共同整合一种失败过的炎炎症药剂，而这种药剂被普遍认为确实整合出一种放射治疗脱发的药剂。详细中文名路透社：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.